Monday, September 17, 2012
German regulators and industry
are busy arguing over what percentage of drugs are determined to have a benefit
under the country's new pricing law, but what is really important is whether
patients are actually getting innovative drugs, and how regulators and
companies go about modifying the system as it continues to evolve.
On Sept. 3, Josef Hecken, chairman of the German
Federal Joint Committee (G-BA), said criticisms of the AMNOG process
are "unfounded" based on an interim analysis of the system's drug
benefit assessments. He said the results of assessments carried out under AMNOG
are comparable to those from other benefit assessment programs, arguing that
G-BA has found at least some degree of additional benefit for 64% of drugs
assessed to date (see BioCentury, July 16).